Objective To explore the mechanism of Zhilong Huoxue Tongyu capsule in the treatment of atherosclerosis(AS) based on network pharmacology. Methods TCMSP, TCMID and other databases were devoted to screen out the active ingredients and targets of Zhilong Huoxue Tongyu capsule. The AS targets were obtained from GeneCard and DisgeNET databases, and the drug and disease intersection targets were selected. The PPI interaction network diagram of target was constructed by String11.0 database, and "drug-active ingredient-disease-target" network diagram, GO function and KEGG signaling pathway enrichment analysis were drawn by Cytoscape3.9.0 software. Results Zhilong Huoxue Tongyu capsule regulates AGE-rage, HIF-1, Apelin and other signaling pathways by acting on L6, TNF, VEGFA, CCl2, MMP9, NOS3 and other key targets through 58 active components of astragalus saponins, astragalus polysaccharide, kahamferol and quercetin. It ultimately affects inflammatory response, oxidative stress, angiogenesis, apoptosis and other biological processes to treat AS. Conclusion Zhilong Huoxue Tongyu capsule has the characteristics of multi-component, multi-target and multi-path mechanism in the treatment of AS.